Clinical observation of oxaliplatin combined with S1 capsule in the treatment of advanced gastric cancer

doi:10.3969/j.issn.1006-7795.2013.03.024

Abstract

Abstract:

Objective To investigate the safety and effectiveness of S-1 capsule combined with oxaliplatin in the treatment of advanced gastric cancer.Methods Fifty-two patients with advanced gastric cancer were treated with the chemotherapy: composed of S-1 capsule 80 mg·m^-2·d^-1, twice daily, oral, d_1－14;oxaliplatin 130 mg·m^-2, intravenous drip, d₁. One treatment cycle covered 3 weeks. The effects and toxicities were evaluated after 4 cycles.Results The effective rate was 44.2% (23/52). The clinical beneficial response was 76.9%(40/52). The main side effects included myelosuppressio,gastrointestinal reactions and neurotoxicity.Conclusion S-1 capsule combined with oxaliplatin is effective in the treatment of advanced gastric cancer, and the toxicities can be tolerated. These results indicate that further clinical study and application are warranted.

Key words: S-1 capsule, oxaliplatin, advanced gastric cancer, chemotherapy

CLC Number:

R 735.2

KONG Man, PEI Wenzhong, YANG Jiandong. Clinical observation of oxaliplatin combined with S1 capsule in the treatment of advanced gastric cancer[J]. Journal of Capital Medical University, 2013, 34(3): 446-449.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.03.024

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I3/446

References

[1] Higuchi K, Phan A, Ajani J A.Gastric cancer:advances in adjuvant and adjunct therapy[J].Curr Treat Options Oncol,2003,4(5):413-419.

[2] 秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652.

[3] 曹妮达,赵爱光,朱莹杰,等.进展期胃癌化疗疗效的中国文献分析[J].世界华人消化杂志,2008,16(4):436-442.

[4] Therasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States.National Cancer Institute of Canada[J].J Natl Cancer Inst,2000,92(3):205-216.

[5] Wagner A D,Grothe W,Haerting J, et al.Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.

[6] 曹锋,王亚军,李菲.胃癌辅助放化疗研究进展[J].现代肿瘤医学,2010,18(1):202-204.

[7] 郭锰; 进展期胃癌术后腹腔化疗的临床疗效分析[J].中华肿瘤防治杂志,2011,18(5):374-376.

[8] 甄四虎, 侯会池,王少文,等.腹腔镜辅助下进展期胃癌根治术56例分析[J]. 解放军医药杂志,2012,24(3):32-34.

[9] 张国伟,宋丽杰.进展期胃癌化疗现状与进展[J]. 临床药物治疗杂志,2009,7(5):14-18.

[10] Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1,a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000,58(3): 191-197.

[11] Tanaka F, Fukuse T, Wada H, et al.The History,Mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents[J].Curr Pham Biotechnol,2000,1(2):137-164.

[12] Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J].Gastric Cancer,2003,6 suppl 1:71-81.

[13] Yoshisue K, Hironaga K, Yamaguchi S, et al.Reduction of 5-fluorouracil (5-Fu) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase(TS) in GI tissue by repeated simultaneous administration of potassium oxonate (OXO) in rat[J]. Cancer Chemother Pharmacol,2000,46(1):51-56.

[14] 林万隆,陈强.奥沙利铂的药理作用及临床应用[J].中国肿瘤临床, 2000,27(11):872-874.

[15] 林俊,朱俊,黄世明.奥沙利铂联合ELF方案治疗晚期胃癌的临床观察[J].中华肿瘤防治杂志,2011,18(2):140-141.

[16] Koizumi W, Narahara H, Hara T, et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.

[17] Zaniboni A, Meriggi F. The emerging role of oxaliplatin in the treatment of gastric cancer[J].J Chemother,2005,17(6):656-662.